Prescription drug · NDA
Triesence (triamcinolone acetonide) NDC 0078-0897
Triamcinolone acetonide 40 mg/mL · Injection, Suspension · Ophthalmic · Novartis Pharmaceuticals Corporation
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0078-0897-78 | 00078089778 | 1 BLISTER PACK in 1 CARTON (0078-0897-78) / 1 VIAL, GLASS in 1 BLISTER PACK / 1 mL in 1 VIAL, GLASSMarketed from Oct 1, 2024 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Triesence
- Generic name (nonproprietary)
- triamcinolone acetonide
- Active ingredients
- Triamcinolone acetonide — 40 mg/mL
- Dosage form
- Injection, Suspension
- Route
- Ophthalmic
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 022048
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 0078-0897_4e6e468e-47e6-3f48-e063-6294a90a035dSPL ID 4e6e468e-47e6-3f48-e063-6294a90a035dSPL set ID 22692d92-1359-9252-e063-6394a90ab669RxCUI 1086259, 1792144UNII F446C597KA
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400078089778followed by a unit qualifier and the quantityPackage 00078-0897-78. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
TRIESENCE suspension is a synthetic corticosteroid indicated for: • Treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. ( 1.1 ) • Visualization during vitrectomy. ( 1.2 ) 1.1 Ophthalmic Diseases TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for: • sympathetic ophthalmia, • temporal arteritis, • uveitis, and • ocular inflammatory conditions unresponsive to topical corticosteroids. 1.2 Visualization During Vitrectomy TRIESENCE suspension is indicated for visualization during vitrectomy.
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 022048
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Triesencetriamcinolone acetonide | Triamcinolone acetonide 40 mg/mL | Injection, SuspensionOphthalmic | Harrow Eye, LLC | 82667-800 |